Cefuroxime axetil

Overview

Cefuroxime axetil is an orally effective broad-spectrum β-lactam antibiotic that targets bacterial penicillin-binding proteins (PBPs, such as PBP3 and PBP1). Cefuroxime axetil inhibits cell wall synthesis, leading to bacterial lysis and death, with a minimum inhibitory concentration (MIC) of 0.12-4 mg/L for non-typeable Haemophilus influenzae (NTHi). Cefuroxime axetil is hydrolyzed by esterase to the active ingredient Cefuroxime ( HY-B1256A ) after oral absorption. Topical administration of Cefuroxime via bioadhesive nanoparticles (BNPs) can prolong the drug's retention time in the middle ear (≥7 days). Cefuroxime axetil can be used in the study of otitis media (especially NTHi infection ). Cefuroxime axetil can achieve precise antibacterial effects through oral or topical nano-delivery systems, reducing systemic exposure and the risk of antibiotic resistance.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > Bacterial Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Antibiotic

Product Information

• Catalog No.: HY-B1325
• CAS No.: 64544-07-6
• Molecular Formula: C20H22N4O10S
• Molecular Weight: 510.47
• Purity: 99.29%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.08 mg/mL (4.07 mM); Clear solution
• Availability: In-stock

Source

Original product source